Drug intelligence / Profile preview

MBTC-DT2-EVs

Development stage: Preclinical
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

MBTC-DT2-EVs is an extracellular vesicle (EV)-based therapeutic candidate being developed by Stemmedicare for the treatment of Type 2 diabetes. The drug is produced using Stemmedicare's proprietary immune-tolerized EV platform, which aims to provide a therapeutic approach that avoids immune rejection while delivering regenerative or immunomodulatory signals. While the specific molecular targets and mechanism of action have not been publicly disclosed, the therapy is designed to address the underlying metabolic and inflammatory components of Type 2 diabetes. It is currently in the preclinical stage of development as a candidate for further clinical evaluation.

Other names: MBTC-DT2-EVs-Stemmedicare-extracellular vesicles (EVs)-Type 2 Diabetes

Beyond the preview

Go deeper on MBTC-DT2-EVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-DT2-EVs.

Explore the full profile